Sitemap - 2026 - The Oncology Shot with Timothee Olivier

The Risk of Uninformative Trials: Statistical Considerations in Radiotherapy Trials

Do we need to be reassured about surrogates? My take in The BMJ.

Currency of Influence in Oncology

My MD-Anderson Cancer Center Madrid Hospiten Talk

Not One, but Two Papers! What Daraxonrasib’s Recent Results Mean for Ongoing and Future Trials

What to look for in NATALEE’s 6-year overall survival results: post-protocol care.

The forgotten question: does each drug actually matter?

My Fribourg talk, in French! Statistics in Oncology in Practice

A Cultural Gap: How Many Patients With Metastatic Pancreatic Cancer Do Not Start Systemic Therapy?

“Chemo‑free” is not always better: the FDA withdrawal of adagrasib in colorectal cancer

Daraxonrasib Is FDA-Approved: Both Good News and Bad News

Beyond Cross-Trial Comparisons: What Digitized Survival Curves Can Really Tell Us

Sham Controls and Tumor Treating Fields: Does the Ethical Argument Hold?

EMA and FDA Advocate Removing Amgen’s Drug from the Market: How Unblinded Personnel Manipulated the ADVOCATE Trial

Additional Insights Into Early Daraxonrasib Data

World-first tumour-agnostic reimbursement for dual immunotherapy (ipilimumab plus nivolumab), an academic debate, and the DART trial

RASolute 302 (daraxonrasib) in metastatic pancreatic cancer: a revolution?

An Eagle Eye on AQUILA Survival Data. Our New Paper Is Out. IQWiG Wins, OpenEvidence Fails.

The Chinese Immunotherapy That Passed the Dutch Test, and How To Assess What is Expected to Be a Tsunami of Immunotherapies.

An outstanding source of trial data lacking from publications: IQWiG assessment reports. The NIAGARA trial example.

My IQWiG lecture in Cologne! What a great audience and team!

The BREAKING-ICE App© V2.0 is out! Enjoy automated explorations and a new companion KM digitizer App.

The Imbalance of NCCN Guidelines: Quick to Implement, Slow to Let Go

Critical Appraisal in Breast Cancer: The Essentials in 30 Minutes.

The PATINA trial – palbociclib maintenance in metastatic breast cancer.

The puzzle of PARP inhibitors plus ARPI in Prostate Cancer: 12 mutations, 3 trials, and 5 different labels.